Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission

Blood

Volumn 116, Issue 17, 2010, Pages 3157-3162

  Gorin, Norbert Claude ^a,b   Labopin, Myriam ^a,b   Reiffers, Josy ^c,k   Milpied, Noel ^c   Blaise, Didier ^d   Witz, Francis ^e   De Witte, Theo ^f   Meloni, Giovanna ^g   Attal, Michel ^h   Bernal, Teresa ⁱ   Rocha, Vanderson ^b,j  

^a HÔPITAL SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e CHU NANCY BRABOIS   (France)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h TOULOUSE UNIVERSITY HOSPITAL   (France)

ⁱ University Hospital of Asturias   (Spain)

^j SAINT LOUIS HOSPITAL   (France)

^k INSTITUT BERGONIÉ   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; AUTOGRAFT; AUTOTRANSPLANTATION; CANCER RELAPSE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REMISSION; STEM CELL; T LYMPHOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; DISEASE-FREE SURVIVAL; HUMANS; LEUKAPHERESIS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 78049386808     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-11-252197     Document Type: Article

References (34)

1. Linker C. The role of autologous transplantation for acute myeloid leukemia in first and second remission. Best Pract Res Clin Haematol. 2007;20(1):77-84. (Pubitemid 46300056)
2. Burnett AK, Goldstone AH, Stevens RMF, et al. Randomised comparison of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC-AML 10 trial. Lancet. 1998;351(9104):700.
3. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339(23):1649-1656.
4. Gorin NC. Autologous stem cell transplantation in acute myelocytic leukemia. Blood. 1998;92(4):1073-1090.
5. Gorin NC. Autologous stem cell transplantation for adult acute leukemia. Curr Opin Oncol. 2002;14(2):152-159. (Pubitemid 34235047)
6. Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as post remission therapy in adult acute myeloid leukemia. Blood. 1997;90(8):2978-2986.
7. Linker CA. Autologous stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplant. 2003;31(9):731-738.
8. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia: European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups [see comments]. N Engl J Med. 1995;332(4):217-223.
9. Gratwohl A, Passweg J, Baldomero H, et al. Blood and marrow transplantation activity in Europe 1997: European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1999;24(3):231-245.
10. Gratwohl A, Baldomero H, Schmid O, et al. Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003. Bone Marrow Transplant. 2005;36(7):575-590.
11. Gratwohl A, Baldomero H, Frauendorfer K, et al. The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products. Bone Marrow Transplant. 2008;41(8):687-705.
12. Gorin NC, Labopin M, Blaise D, et al. Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission. J Clin Oncol. 2009;27(24):3987-3993.
13. Keating S, Suciu S, de Witte T, et al. The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial. Leukemia. 2003;17(1):60-67.
14. Gooley TA. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706.
15. Andersen PK, Klein JP, Zhang MJ. Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18(12):1489-1500.
16. Byar DP. Identification of prognostic factors. In: Buyse ME, ed. Cancer Clinical Trials Methods and Practice. Oxford, United Kingdom: Oxford Medical Publications; 1988:423-443.
17. Hoogard P. Frailty model for survival data. Lifetime Data Anal. 1995;3:255-273.
18. Gorin NC, Najman A, Duhamel G. Autologous bone-marrow transplantation in acute myelocytic leukaemia. Lancet. 1977;1(8020):1050.
19. Gorin NC. Stem cell in vitro purging for autologous transplantation. In: Armitage JO, Antman KH, eds. High Dose Cancer Therapy, Pharmacology, Hematopoietins, Stem Cells. Philadelphia, PA: Lippincott Williams and Wilkins, 2000:355-391.
20. Gorin NC, Aegerter P, Auvert B, et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood. 75(8):1990;1606-1614.
21. Gorin NC, Labopin M, Meloni G, et al. Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide: European Co-operative Group for Bone Marrow Transplantation (EBMT). Leukemia. 1991;5(10):896-904.
22. Miller CB, Rowlings PA, Zhang MJ, et al. The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia. Exp Hematol. 2001;29(11):1336-1346. (Pubitemid 33033311)
23. Brenner MK, Rill DR, Moen RC, et al. Genemarking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 1993;341(8837):85-86.
24. Gorin NC, Labopin M, Laporte JP, et al. Importance of marrow dose on posttransplant outcome in acute leukemia: models derived from patients autografted with mafosfamide-purged marrow at a single institution. Exp Hematol. 1999;27(12):1822-1830.
25. Laporte JP, Douay L, Lopez M, et al. One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10-year single institution experience. Blood. 1994;84(11):3810-3818.
26. Reiffers J, Bernard P, David B, et al. Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia. Exp Hematol. 1986;14(14):312-315.
27. To LB, Haylock DN, Kimber RJ, et al. High levels of circulating haemopoietic stem cells in very early remission from acute non-lymphoblastic leukaemia and their collection and cryopreservation. Br J Haematol. 1984;58(3):399-410.
28. Laporte JP, Gorin NC, Feuchtenbaum J, et al. Relapse after autografting with peripheral blood stem cells. Lancet. 1987;2(8572):1393.
29. Mehta J, Powles R, Singhal S, et al. Peripheral blood stem cell transplantation may result in increased relapse of acute myeloid leukaemia due to reinfusion of a higher number of malignant cells. Bone Marrow Transplant. 1995;15(4):652-653.
30. Sanz MA, De La Rubia J, Sanz GF, et al. Busulfan plus cyclophosphamide followed by autologous blood stem-cell transplantation for patients with acute myeloblastic leukemia in first complete remission: a report from a single institution. J Clin Oncol. 1993;11(9):1661-1667.
31. Vellenga E, Young DC, Wagner K, et al. The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood. 1987;69(6):1771-1776.
32. Brugger W, Bross KJ, Glatt M, et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood. 1994;83(3):636-640.
33. Barnett D, Granger V, Kraan J, et al. Reduction of intra- and inter-laboratory variation in CD34+ stem cell enumeration by the use of stable test material, standard protocol and targeted training. Br J Haematol. 2000;108(4):784-792. (Pubitemid 30304511)
34. Keeney M, Brown W, Gratama J, Papa S, Lanza F, Sutherland R. Single platform enumeration of viable CD34+ cells. J Biol Regul Homeost Agents. 2003;17(3):247-253.